Sangamo Therapeutics (SGMO) Earns “Neutral” Rating from Wedbush

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “neutral” rating restated by investment analysts at Wedbush in a note issued to investors on Monday. They currently have a $6.00 price target on the biopharmaceutical company’s stock. Wedbush’s price target would indicate a potential downside of 69.39% from the stock’s previous close.

Several other research analysts have also weighed in on the stock. Barclays initiated coverage on shares of Sangamo Therapeutics in a report on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 price objective for the company. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Wednesday, November 15th. Piper Jaffray Companies raised shares of Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price objective for the company in a report on Wednesday, November 15th. Finally, BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 29th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Sangamo Therapeutics presently has an average rating of “Buy” and a consensus price target of $18.83.

Shares of Sangamo Therapeutics (SGMO) opened at $19.60 on Monday. The firm has a market cap of $1,656.61, a price-to-earnings ratio of -28.41 and a beta of 2.87. Sangamo Therapeutics has a fifty-two week low of $3.60 and a fifty-two week high of $22.85. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. The company had revenue of $11.81 million during the quarter, compared to analyst estimates of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The firm’s revenue for the quarter was up 333.0% compared to the same quarter last year. During the same period last year, the business earned ($0.27) EPS. equities analysts anticipate that Sangamo Therapeutics will post -0.73 earnings per share for the current year.

In other news, Director Saira Ramasastry sold 5,000 shares of Sangamo Therapeutics stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $14.67, for a total value of $73,350.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $73,350. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steven J. Mento sold 11,520 shares of Sangamo Therapeutics stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $20.59, for a total transaction of $237,196.80. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $102,950. The disclosure for this sale can be found here. Over the last three months, insiders have sold 89,953 shares of company stock valued at $1,618,193. 5.50% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Alexandria Capital LLC acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at about $15,179,000. Virtus Fund Advisers LLC acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at about $354,000. UBS Asset Management Americas Inc. boosted its holdings in shares of Sangamo Therapeutics by 72.7% in the 4th quarter. UBS Asset Management Americas Inc. now owns 37,122 shares of the biopharmaceutical company’s stock valued at $609,000 after buying an additional 15,624 shares during the period. BlackRock Inc. boosted its holdings in shares of Sangamo Therapeutics by 2.1% in the 4th quarter. BlackRock Inc. now owns 6,871,509 shares of the biopharmaceutical company’s stock valued at $112,691,000 after buying an additional 138,348 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Sangamo Therapeutics by 4.9% in the 4th quarter. Bank of New York Mellon Corp now owns 392,713 shares of the biopharmaceutical company’s stock valued at $6,440,000 after buying an additional 18,404 shares during the period. 64.22% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/02/12/sangamo-therapeutics-sgmo-earns-neutral-rating-from-wedbush.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply